Roivant Sciences is trading at $42.33, up +21.19%, following the announcement of positive Phase 2 PHocus topline results for mosliciguat. The positive results from the Phase 2 PHocus study of mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD) were announced today, September 8, 2026. Roivant will also host an investor webcast at 8:00 a.m. ET to discuss the findings.